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Heavy ion carcinogenesis and  
human space exploration
Marco Durante and Francis A. Cucinotta
Abstract | Before the human exploration of Mars or long-duration missions on the 
earth’s moon, the risk of cancer and other diseases from space radiation must be 
accurately estimated and mitigated. space radiation, comprised of energetic 
protons and heavy nuclei, has been shown to produce distinct biological damage 
compared with radiation on earth, leading to large uncertainties in the projection 
of cancer and other health risks, and obscuring evaluation of the effectiveness of 
possible countermeasures. Here, we describe how research in cancer radiobiology 
can support human missions to Mars and other planets.
Space radiation, isolation (psychosocial 
problems) and microgravity-induced 
physiological changes are the main health 
problems for the exploration of the Solar 
system. Among the various health risks, 
carcinogenesis caused by exposure to space 
radiation is now generally considered the 
main hindrance to interplanetary travel for 
the following reasons: large uncertainties 
are associated with the projected cancer 
risk estimates, no simple and effective 
countermeasures are available, and the large 
uncertainties prevent determining the effec-
tiveness of countermeasures. Optimizing 
operational parameters such as the length 
of space missions and crew selection for 
age and gender, or applying mitigation 
measures, such as radiation shielding or use 
of biological countermeasures, can reduce 
risk, but these approaches are clouded by 
uncertainties.
Space radiation is comprised of high-
energy protons and high charge (Z) and 
energy (E) nuclei (HZE), whose ionization 
patterns in molecules, cells and tissues, and 
the resulting initial biological insults, are 
distinct from typical terrestrial radiation. 
Terrestrial radiation is largely characterized 
by low linear energy transfer (LET) radia-
tion (X-, β- or γ-rays), with the exception 
of the dose localized to the lungs caused by 
low-energy α-particles from radon gas. HZE 
nuclei dominate the exposure in deep space 
(interplanetary travels), whereas trapped 
protons also contribute to the equivalent 
dose absorbed by crews in low-Earth-orbit 
(Space Shuttle flights or International 
Space Station). BOX 1 and FIG. 1 provide a 
physics primer on space radiation types 
and the differences in energy deposition in 
biomolecules, cells and tissues. The relation-
ships between the early biological effects of 
HZE nuclei and the probability of cancer 
in humans are poorly understood1–3, and 
it is this missing knowledge that leads to 
large uncertainties in projecting cancer risks 
(BOX 2 and FIG. 2) during space exploration.
In this Perspective, we will first discuss 
the issue of radiation risk in space: what is 
an ‘acceptable’ risk, how we can estimate it 
and what are the associated uncertainties. 
we will then discuss heavy-ion radiobiology, 
the key research field needed to reduce risk 
uncertainty. Finally, we will deal with the 
problem of countermeasures, both physical 
(shielding), biomedical (radioprotectors) 
and genetic (screening of radiosensitive 
individuals).
Acceptable levels of risk for astronauts
Space exploration is a high-risk endeavour, 
given the prospects of vehicle or life-support- 
system failure4,5. Acceptable levels of risk 
must take into account the value of the 
mission for humanity and science, the stake-
holders for risk acceptance, which include 
astronauts and their loved ones, tax-payers 
and the scientific community, and the risk–
benefit ratio6. A goal of <1% mission failure 
risk is used in the design of launch, life- 
support and crew-return systems. Radiation 
risks must also be considered, including 
cancer morbidity and mortality that would 
be projected to occur years after the mis-
sion. The National Aeronautics and Space 
Administration (NASA) sets risk acceptance 
levels at 3% risk of exposure-induced death 
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(REID) for radiation carcinogenesis. This 
level is several times higher than other mis-
sion design risk levels. However, this may be 
appropriate because the life loss for cancer 
death, at least for low-LET radiation, is 
estimated at about 15 years, compared with 
the remainder of life for a mission failure. 
Risk levels much higher than 3% would be 
difficult to accept owing to safety concerns, 
but also because other fatal radiation risks 
such as heart and digestive diseases7 become 
likely at higher exposure levels, making 
the radiation risk even more problematic. 
Furthermore, overall uncertainties in space 
radiation cancer projections are about five-
fold higher at the 95% confidence level8,9 than 
the median risk projection and it is therefore 
not possible, with the current state of knowl-
edge of cancer biology, to judge if risks are 
higher or lower than safety standards.
Estimating space cancer risk
The differences in physical characteristics 
and biological effects of celestial versus ter-
restrial radiation make the usefulness of γ- 
or X-ray exposure data in predicting heavy 
ion effects extremely limited. The scaling of 
mortality rates for space radiation risks to 
astronauts from atomic bomb survivors and 
patients exposed to therapeutic radiation 
introduces many uncertainties1,2,8 into risk 
estimates (BOX 2, FIG. 2). A key assumption 
in current methods of projecting cancer 
risk is that radiation-induced cancer 
mortality rates based on epidemiological 
studies of the atomic bomb survivors can be 
scaled to other populations, dose rates and 
radiation types. Two scaling parameters 
with large uncertainties are the dose and 
dose-rate effectiveness factor (DDREF), 
which scales for reduced dose and dose 
rate (<0.05 Gy/h), and, especially, the 
‘radiation quality factor’, Q, which estimates 
the increased effectiveness of HZE nuclei 
compared with γ-rays for the same dose. 
Risks for extended missions to the Moon 
and the Mars exploration mission exceed 
3% for most scenarios with upper 95% 
confidence levels near 15% risk of death9. 
However, there are important questions 
with regard to the correctness of any scaling 
approach because of qualitative differences 
between the biological effects of HZE ions 
and γ-rays.
Biological effectiveness of HZE nuclei
Energy deposition. The initial bio-
physical events induced by radiation in 
biomolecules, cells and tissues are key to 
understanding differences between γ-rays 
and the heavy ions in space. Energy deposi-
tion by HZE nuclei consists of a localized 
high-LET contribution along the trajectory 
of each particle and lateral extension of 
low-LET energetic electrons (δ-rays) many 
microns from the ion’s path10,11. The dose 
deposited in a biomolecule is described 
by microdosimetry concepts (FIG. 1). For 
radiation effects on small DNA segments, 
heavy ions are several times more effective 
than X-rays11,12. Differences between radia-
tion types also occur at the level of chro-
mosomal loops or whole chromosomes, 
leading to distinct spatial patterns of DNA 
lesions for HZE nuclei and X-rays13.
DNA damage. DNA damage and conse-
quent mutations are generally accepted 
as the initiating event of the multi-step 
carcinogenic process, although recent 
evidence demonstrates the importance 
of non-targeted effects independent of 
DNA lesions1. Among the many radia-
tion-induced lesions, DNA double-strand 
breaks (DSBs) are considered the key 
precursors of most early and late effects. 
There are qualitative differences between 
high- and low-LET radiation both in the 
induction and repair of DNA damage14–17. 
The number of DNA single-strand breaks 
(SSBs) and DSBs produced by radiation 
varies little with radiation type, but for 
high-LET radiation a higher fraction of 
DNA damages are complex, that is, are 
clusters containing mixtures of two or more 
of the various types of damages (SSB, DSB 
and so on) within a localized region of 
DNA. Complex damage is uncommon for 
endogenous damage or low-LET radiation, 
and has been associated with the increased 
relative biological effectiveness (RBE, see 
BOX 1) of densely ionizing radiation18.19.
The repair of DSBs is known to occur 
through the non-homologous end-joining 
(NHEJ) and homologous recombination 
(HR) pathways20–23. Foci experiments using 
immunohistochemistry for antibodies to 
important NHEJ and HR repair proteins 
have been performed recently with X-rays 
and HZE nuclei. Key differences between 
X-rays and HZE nuclei are rapidly apparent, 
including dynamic and larger foci sizes in the 
first 2 h after irradiation for HZE nuclei com-
pared with X-rays24, the appearance of streaks 
of foci indicating the path of a particle track, 
and the persistence and slower removal of 
foci for HZE nuclei25. DNA damage response 
proteins26–28, such as ataxia-telangiectasia 
mutated (ATM), ataxia-telangiectasia and 
Rad3-related (ATR)29, Artemis (also known 
as DCLRE1C) and NBS1 (also known as 
NBN), might have a large role in the repair of 
complex DSBs and are an important focus 
of current space radiation research.
Live-cell imaging of DNA repair proteins 
induced with high-intensity laser micro-
beams is now widely used to study the kinet-
ics of DNA damage responses30–32. Live-cell 
imaging with heavy ions has shown that 
DNA repair proteins are recruited to sites of 
heavy ion hits in cell nuclei of fibroblast cells 
 Box 1 | Basic radiation physics
Astronauts are exposed to protons and high energy and charge (HZE) ions, along with 
secondary radiation including neutrons and recoil nuclei that are produced by nuclear 
reactions in spacecraft or tissue. The nuclear charge of the galactic cosmic radiation (GCR) 
extends from hydrogen to uranium; however, nuclei heavier than iron (Z=26) are infrequent 
(FIG. 1a). The energy spectrum of the GCR peaks at about 85% of the speed of light, or 1 GeV 
per nucleon in energy units, and consequently these particles are so penetrating that 
shielding can only partially reduce the doses absorbed by the crew. The number of nuclei per 
unit area is denoted by the fluence, F. The large ionization power of HZE ions with Z>2 makes 
them the major contributor to the risk, in spite of their lower fluence than protons. The 
absorbed dose (D; measured in Gy) is the amount of energy deposited per unit mass of 
material and is calculated from the fluence by multiplying it by the linear energy transfer 
(LET), L, such that D = F × L.
Because the types of radiation in space are diverse in how they deposit energy, absorbed 
dose is a poor descriptor of biological effects. If the same biological effect (for example, 
same cell survival or mutation frequency) is induced by a reference radiation (for example, 
X­rays) dose DX and by a dose Dt of a test radiation (for example, HZE ions), then the ratio 
DX/Dt is defined as relative biological effectiveness (RBE) of the test radiation. The RBE 
depends on several parameters, including LET, particle velocity and charge, dose and dose­
rate, biological endpoint and oxygen concentration. To estimate biological effects it is 
customary to scale the absorbed dose by a quality factor Q(LET), which is estimated from 
the measured RBE values for late effects. Q ranges from 1 at low LET (<10 keV/µm) to 30 at 
high LET (around 100 keV/µm), and then decreases at very high LET values because of what 
is called over­kill or wasted energy. The quantity H = D × Q is called the dose equivalent and 
is measured in sievert (Sv).
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within seconds. No large-scale chromatin 
movements are associated to the repair activ-
ity33, yet some movement is observed in the 
repair protein foci. Image analysis of γ-H2AX 
and TP53BP1 protein dynamics in human 
epithelial cells fixed following exposure to 
Fe ions suggests that DNA lesions do indeed 
move to nuclear sub-domains for more 
efficient repair34.
To date, there is no experimental evi-
dence that different repair pathways are 
invoked following exposure to heavy ions or 
sparsely ionizing radiation. However, emerg-
ing evidence does suggest significant differ-
ences in gene expression at early times after 
irradiation35, and that LET has an influence 
on the dynamics of chromatin movements 
following irradiation36–37. More studies com-
paring HZE nuclei and X-rays are necessary 
to assess the recruitment kinetics of different 
proteins at sites of DNA damage.
Chromosomal aberrations. DNA DSBs 
misrepaired or left unrepaired eventually 
appear as chromosomal aberrations38. 
Heavy charged particles are effective at 
producing chromosomal exchanges with 
RBE values exceeding 30 in interphase (as 
visualized using premature chromosome 
condensation) and 10 at the first post-
irradiation mitosis for energetic heavy 
ions39. However, lower values are observed 
in vivo40–41. Besides, cytogenetic studies 
reveal a much higher level of complexity 
of chromosomal rearrangements induced 
by heavy ions compared with sparsely ion-
izing radiation (FIG. 3) — that is, rearrange-
ments induced by heavy ions involve 
a higher number of chromosomes and 
breakpoints42, and include both intra- and 
inter-chromosomal exchanges43,44. However, 
most of these complex rearrangements ulti-
mately lead to cell death. In fact, only a few 
complex exchanges are found in the bone 
marrow of mice after 1 week of exposure 
to Fe ions41, and the fraction of aberrant 
cells in the progeny of human lymphocytes 
exposed to heavy ions is close to the 
frequency observed in samples exposed to 
γ-rays45 (FIG. 3e).
Interestingly, chromosomal aberrations 
can be measured in the blood lymphocytes 
of astronauts returning from long-term 
space flights and can then be used to test 
dose and risk estimates from current 
models46. In fact, chromosomal aberrations 
in blood lymphocytes are considered a 
validated biomarker of cancer risk46–48, and 
can be used as biodosimeters to estimate 
equivalent dose in exposed individuals49. 
Biodosimetry studies performed by NASA50–51 
and in Russian cosmonauts52 show that the 
measured chromosomal rearrangements in 
crew members returning from space flight 
are consistent with current models, although 
the biological results are also affected by 
a large experimental uncertainty at low 
doses. However, yields of translocations and 
dicentrics decrease as a function of time 
after exposure during the space mission, and 
it is unclear what the influence of time since 
test should be on risk estimates51. For cos-
monauts involved in multiple spaceflights, 
the final yield of aberrations does not seem 
to be additive46. Further, in experienced 
cosmonauts with a total of about 2 years in 
space, the total yield of the aberrations is 
close to the measured background before the 
first flight52. The real significance of these 
findings remains to be elucidated.
New approaches to cancer risk estimates
The fundamental problem in space radiation 
research is the absence of sufficient evidence 
that models of cancer risk sufficiently 
describe the biology of tumour formation 
from HZE nuclei. Animal studies generally 
demonstrate that HZE nuclei have a higher 
carcinogenic effectiveness than low-LET 
radiation53–56, but RBE values are difficult 
to quantify because of statistical uncertain-
ties, which in many experiments prevents 
a definitive conclusion regarding the risks 
at low doses or dose rates. Additionally, 
the large variety of radiation types in space 
precludes an extensive study of tumour types 
in different strains of mice with different ion 
or dose regimes.
Tissue effects not dependent on direct 
DNA damage that have been associated 
with cancer initiation or progression include 
genomic instability57–61, extracellular matrix 
remodeling62, persistent inflammation63 
and oxidative damage64–66. Research on 
carcinogenesis continues to debate what 
is cause and what is effect67; that is, is the 
cause DNA damage and mutation leading 
to genomic instability, or is it extracellular 
matrix remodelling and other non-targeted 
effects?  Space research benefits from these 
studies, but they must be extended to test 
the effects of HZE nuclei. HZE nuclei can 
modify these responses, as well as others that 
include DNA changes, in ways distinct from 
other radiation types or carcinogens, which 
complicates our ability to estimate and 
design effective mitigations.
Major radiation-induced solid cancer 
sites include breast, thyroid, colon and 
lung68. Lung cancer makes up about one-
third of the cancers attributable to radiation 
Figure 1 | Space radiation environment and shielding. a | The contribution 
in fluence (green), dose (blue), and dose equivalent (red) of different nuclei 
in galactic cosmic radiation. b | How the cancer risk for a mission to Mars 
varies for increasing amounts of shielding materials after considering the 
tissue shielding of the human body. red and black lines represent water and 
aluminium shields, respectively. Lower curves are median estimates, and 
upper curves provide the upper 95% confidence limits. This calculation shows 
that even heavy shields will not be able to reduce the risk by a large factor.
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observed in the atomic-bomb survivors68 
and nuclear-reactor workers69. However, 
risk estimates are confounded by the use of 
tobacco by a large fraction of the exposed, 
and the large tobacco risk often precludes 
identification of the radiation effect with 
high accuracy68. A small number of astro-
nauts have smoked in the past and virtually 
none do so currently. A new experimental 
model that allows the study of individual or 
combinations of mutations in lung cancer 
progression has been recently developed70:   
a three-dimensional co-culture of telomerase 
reverse transcriptase (TERT)-immortalized 
bronchial epithelial cells interacting with 
a stroma layer. Over 30 primary lines have 
been immortalized to study how specific 
genetic components influence radiation-
induced transformation. The results illus-
trate the extreme inefficiency with which 
X-rays transform primary cell lines. Studies 
using the three-dimensional co-culture 
models with Fe nuclei are being conducted 
and will be especially important owing to 
the limitations in animal models of human 
lung carcinogenesis71.
Research on the mechanisms of radiation-
induced mammary carcinogenesis has high-
lighted the importance of tissue regulation 
modifications in the development of cancer. 
Transforming growth factor β1 (TGFβ) 
acts as a tumour suppressor during cancer 
initiation and as a promoter during progres-
sion72. Recent studies of the role of TGFβ 
in tumorigenesis highlight how tissues can 
control a broad range of cellular responses, 
including how TGFβ-null epithelial cells, or 
cells treated with a small-molecule inhibitor 
of TGFβ, show downregulation of DNA 
damage responses, as evidenced by almost 
complete abrogation  of γ-H2AX foci73, and 
induction of an epithelial to mesenchymal 
transition74 after ionizing radiation exposure 
in a primary human cell culture model.
Countermeasures
Even if risk projections and their uncertainties 
are reduced in the next few years, effective 
countermeasures to reduce the biological 
damage produced by ionizing radiation 
remains a long-term goal of space research. 
Such countermeasures might not be neces-
sary for a lunar base, but will probably be 
needed for the Mars mission, and most 
definitely for exploring Jupiter or Saturn’s 
moon Titan or the nearby satellites2. In all 
basic radioprotection textbooks, it is stated 
that there are three means to reduce exposure 
to ionizing radiation: increasing the distance 
from the radiation source, reducing the 
exposure time and shielding. Distance has 
no role in space, as space radiation is omni-
directional. Time in space is likely to be 
increased rather than decreased given plans 
for exploration and colonization. Shielding 
remains a plausible countermeasure, albeit 
a prohibitively costly one in light of current 
launch mass capabilities. Furthermore, 
the present uncertainties in risk projection 
prevent us from determining the true benefit 
of shielding. Other strategies can be effec-
tive in reducing exposure and the effects of 
radiation in space, including the choice of an 
appropriate time of flight, administration of 
drugs or dietary supplements to reduce the 
radiation effects, and crew selection.
Radioprotective agents. The search for 
efficient radioprotectors is a major goal of 
research in radiation protection and therapy. 
Both radiation injury and oxygen poisoning 
occur through the formation of reactive 
oxygen species; therefore, antioxidants can be 
efficiently used to prevent the damage75.
Phosphorothioates and other amino-
thiols, which are usually administered 
shortly before exposure, are so effective in 
tissue protection against ionizing radia-
tion that one specific compound (Ethyol, 
also known as amifostine or wR-2721) is 
approved in many countries for clinical use 
during chemotherapy and radiotherapy can-
cer treatments76. unfortunately, amifostine 
and other thiols have significant side effects, 
including nausea, vomiting, vasodilatation 
and hypotension77, precluding their use in 
space flights, except in case of an intense 
solar-particle event, which could produce 
acute radiation syndromes and even be 
life-threatening for an unprotected crew. 
Naturally occurring antioxidants are less 
effective than phosphorothioate agents 
in protection against high-dose acute 
radiation burden. However, nutritional 
antioxidants have a low toxicity, can be 
used for prolonged periods of time and 
seem to have a key role in the prevention of 
cancer78–79. A diet rich in fruit and vegetables 
significantly reduced the risk of cancer 
in the atomic-bomb survivor cohort80. 
Retinoids and vitamins (A, C and E) are 
probably the best-known and most-studied 
natural radioprotectors, but hormones (for 
example, melatonin), gluthatione, super-
oxide dismutase (SOD), phytochemicals 
from plant extracts (including green tea 
and cruciferous vegetables) and metals 
(especially selenium, zinc and copper salts) 
are also under study as dietary supplements 
for individuals overexposed to radiation81, 
including astronauts. In addition, there is 
evidence of reduced antioxidant capacity 
during spaceflight, as shown by reduced 
SOD levels and total antioxidant activity in 
some astronauts returning from missions on 
the International Space Station82.
understanding the effectiveness of 
antioxidants in space is complicated by the 
presence of HZE particles. whereas most of 
the DNA damage induced by γ- or X-rays 
is mediated by free radicals produced in the 
water surrounding the biological molecules 
(indirect effect), for densely ionizing radia-
tion the direct effect predominates, that is, 
atoms in the DNA are directly ionized. 
Therefore, in principle, antioxidants should 
provide reduced or no protection against 
the initial damage from heavy ions, because 
 Box 2 | Key issues in projecting space radiation cancer risks
Ionizing radiation is a well­known carcinogen on Earth. The risks of cancer for X­rays and γ­rays 
have been established at doses above 100 mSv, but there are large uncertainties and ongoing 
scientific debate about cancer risk at lower doses and at low dose rates (<50 mSv/h).
The major uncertainties in risk prediction for space radiation are as follows:
• The effect of radiation quality on biological damage because of the qualitative and quantitative 
differences between space radiation and γ­rays.
• The dependence of risk on dose rates in space and their effects on the biology of DNA repair, 
cell regulation and tissue or organism responses.
• Predicting solar­particle events, including temporal, energy spectrum and size predictions.
• Extrapolation from experimental data to humans.
• Individual radiation­sensitivity factors including genetic, epigenetic, dietary or ‘healthy worker’ 
effects.
The minor uncertainties in risk prediction are as follows:
• Data on galactic cosmic radiation environments.
• The physics of shielding assessments based on the transmission properties of radiation through 
materials and tissue.
• Microgravity effects on biological responses to radiation.
• Errors in human data (statistical, dosimetry or recording inaccuracies).
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scavenging of free radicals will not preserve 
the DNA molecule. However, there is an 
expectation that some benefits should occur 
for persistent oxidative damage related to 
inflammation and immune responses67. 
Some recent experiments suggest that, at 
least for acute high-dose irradiation, efficient 
radioprotection can be achieved by dietary 
supplements even in cases of exposure to 
high-LET radiation. Ascorbate reduces the 
frequency of mutations in human–hamster 
hybrid cells exposed to high-LET C ions83. 
vitamin A strongly reduces the induction 
of fibroma in rats exposed to swift Fe ions84. 
Dietary supplementation with Bowan–Birk 
protease inhibitors85, l-selenomethionine 
or a combination of selected antioxidant 
agents86 could partially or completely prevent 
the decrease in total antioxidant status in the 
plasma of mice exposed to proton or HZE 
particle radiation, as well as neoplastic trans-
formation of human thyroid cells in vitro. 
There is evidence that dietary antioxidants 
(especially those in strawberries) can protect 
the central nervous system from the deleteri-
ous effects of high doses of HZE particles87. 
However, because biological effects are varied 
for low dose-rate compared with acute irra-
diation, new studies for protracted exposures 
will be needed to understand the potential 
benefits of biological countermeasures.
Even if antioxidants can act as radio-
protectors, this does not necessarily 
translate as an advantage for cancer risk. 
If antioxidants protect cells by rescuing 
them from apoptosis, then this may allow 
the survival of damaged cells, which 
eventually can initiate tumour progression. 
Concern about this possibility is sustained 
by a recent meta-analysis of the effects 
of antioxidant supplements in the diet of 
normal subjects88. The authors did not 
find statistically significant evidence that 
antioxidant supplements have beneficial 
effects on mortality. On the contrary, they 
concluded that β-carotene, vitamin A 
and vitamin E seem to increase the risk of 
death. Concerns include rescuing cells that 
not only sustain DNA damage, but also 
those with altered methylation patterns 
following radiation, which can also result 
in genomic instability89. An approach 
to target damaged cells for apoptosis 
might be advantageous for chronic 
exposures to galactic cosmic rays (GCR). 
Radioprotectors tested for acute exposures 
at high doses should be used with care 
— rescuing damaged cells may make the 
problem worse in the long term.
Individual susceptibility. Studying the 
mechanisms and pathways of genetic 
radiosensitivity provides important 
insights into radiation risks to astronauts. 
Studies of historical data sets such as the 
atomic-bomb survivors would need to 
be re-analysed if subsets of the exposed 
cohorts were found to have higher than 
average radiation risks90,91.
Therapeutic misadventures involving 
ataxia telangiectasia patients have dramati-
cally demonstrated the importance of 
genetic susceptibility to radiation damage 
in cancer treatment. ATM homozygotes 
only represent a small fraction of the 
extremely radiosensitive patients, although 
they appear to be the most sensitive. ATM 
heterozygotes, who are also cancer-prone, 
are suspected to represent a large fraction 
of the extremely radiosensitive patients92. It 
has been shown that cells heterozygous for 
ATM mutations are slightly more sensitive 
to radiation-induced neoplastic transforma-
tion than the wild-type93. An increased sen-
sitivity of ATM heterozygotes has also been 
demonstrated in vivo by measuring induc-
tion of cataracts in ATM homozygotes, 
heterozygotes and wild-type mice exposed 
to 0.5–4 Gy X-rays94.
Besides ATM there is the issue of 
whether or not other low-penetrance 
genes can also help determine sensitivity 
to radiation-induced cancer. Genes other 
than ATM can confer radiosensitivity in 
the heterozygous state, for instance, Rad9  
(ReF. 95), BRCA1 and BRCA2 (ReF. 96). In 
addition, cells from unaffected parents of 
retinoblastoma (Rb) patients are radiosensi-
tive, and although the parents do not carry 
the mutant Rb allele, the hypersensitivity 
is similar to that observed in those hetero-
zygous for ATM97. A recent study on 
subjects exposed to high-radiation doses to 
treat ringworm of the scalp (tinea capitis) 
in Israel revealed a strong familial risk of 
radiation-induced meningioma98, suggest-
ing that radiation carcinogenesis might 
be an issue for genetically predisposed 
Figure 2 | Uncertainties in space and terrestrial radiation exposures. 
a | estimates of uncertainties in projecting cancer risks for space from 
terrestrial exposures. several factors, such as radiation-quality effects, 
space physics and microgravity, do not contribute on earth and lead to 
large increases in risk projections. Predicting risks to individuals is dif-
ficult as there are few quantitative measures of individual sensitivity. 
Only a select few individuals enjoy space travel and projecting risks for 
them rather than populations will be of utmost importance for space 
missions to Mars. The extrapolation from experimental models to 
humans is perhaps the greatest challenge to cancer risk assessments. 
b | The uncertainties are larger for astronauts in space than for typical 
exposures on earth; the figure shows the current estimates9 of cancer 
risks and 95% confidence bands for adults of age 40, the typical age of 
astronauts on space missions for several terrestrial exposures and mis-
sions, on the international space station (iss), a lunar colony and the 
projections for a Mars mission. cT, computed tomography.
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subgroups of the general population, rather 
than a random event99.
It is not known whether individuals 
displaying hypersensitivity to low-LET 
radiation will also be universally hypersen-
sitive to HZE nuclei, or if findings at high 
dose and dose rates will hold at low dose 
rates and doses. Mice heterozygous for 
the ATM gene are more sensitive to cata-
ractogenesis than wild type, not only after 
exposure to X-rays, but also after localized 
irradiation with high-energy Fe ions100. 
However, these and other studies show that 
high-LET irradiation has a reduced depend-
ence on genetic background compared with 
low-LET irradiation2.
A predictive assay capable of identifying 
radiation-hypersensitive or cancer-prone 
individuals could be very useful in crew 
selection for long-term space flights. 
However, this assay is neither scientifi-
cally achievable, nor within society norms 
in most countries at the present time. 
ultimately, however, for a high-risk and 
high-cost endeavour such as a mission to 
Mars, screening prospective astronauts 
for increased resistance to space radiation 
might be completely appropriate in order to 
reduce both the risk and the cost associated 
with the mission.
Shielding. For terrestrial radiation workers, 
additional protection against radiation 
exposure is usually provided through 
increased shielding. unfortunately, shield-
ing in space is problematic, especially when 
considering GCR. High-energy radiation 
is very penetrating: a thin or moderate 
shielding is generally efficient in reducing 
the equivalent dose, but as the thickness 
increases, shield effectiveness drops (see 
cancer risk estimates as a function of 
shielding thickness in FIG. 1). This is the 
result of the production of a large number 
of secondary particles, including neutrons, 
caused by nuclear interactions of the GCR 
with the shielding material. These particles 
generally have lower energy, but can have 
higher quality factors than the incident 
cosmic primary particle.
Contrary to the shielding of photons 
on Earth, for which heavy elements such 
as lead are preferred, in space shielding 
effectiveness per unit mass is the high-
est for hydrogen, and decreases with 
increasing atomic number. This has been 
confirmed by computer models such as 
HZETRN101–102, used by NASA, or Geant4 
(ReF. 103), used by the European Space 
Agency (ESA), and accelerator104–106 or 
space-flight measurements107. Although 
liquid hydrogen would display the maxi-
mum performance as shield material, it is 
not at all practical, being a low-temperature 
liquid. Polyethylene could be a good 
compromise, and has been installed in the 
sleeping quarters of the International Space 
Station. unfortunately, most biologically 
dangerous secondary radiation is produced 
in tissue by high-energy GCR nuclei even 
behind hydrogen shielding. with current 
technology, active (magnetic) shielding is 
not yet feasible108–109; passive (bulk) shields 
may be able to reduce the exposure, but 
they are not likely to solve the problem.
Figure 3 | chromosomal aberrations induced by heavy ions. examples of 
complex-type aberrations induced by energetic Fe ions in human peripheral 
blood lymphocytes. complex rearrangements involve a minimum of two 
chromosomes and three breakpoints. a | Polycentric chromosomes visual-
ized by multicolour fluorescence in situ hybridization (mFisH)42: from top to 
bottom, a quadricentric involving both chromosomes 1, chromosome 9 and 
chromosome 6; a dicentric of chromosome 1 and 9, with an insertion 
of  chromosome 3; a tricentric involving both chromosomes 6 and chromo-
some 1. b | A complex rearrangement in chromosome 5 visualized by multi-
colour banding fluorescence in situ hybridization (mBAND; courtesy of 
M. Horstmann). One normal chromosome 5 is visible on the bottom, whereas 
the other is broken into three pieces. Breakpoints can be mapped on chro-
mosome 5 using mBAND. c | A multi-aberrant karyotype, including inter- and 
intra-changes in the progeny of lymphocytes exposed to Fe ions visualized 
by arm-specific mFisH (courtesy of D. Pignalosa). Arm-specific mFisH 
and mBAND show that complex rearrangements can involve both inter- and 
intra-chromosomal exchanges. d | The fraction of complex-type exchanges 
in lymphocytes following exposure to γ-rays or Fe ions. Aberrations were 
measured by mFisH in prematurely condensed chromosomes. clearly, Fe 
ions induce a high fraction of complex-type rearrangements. e | However, 
many of these rearrangements are lethal: in fact, the relative biological 
effectiveness (rBe) for the induction of aberrant cells decreases from inter-
phase (prematurely condensed chromosomes) to first mitosis, and to later 
cell cycles (progeny of irradiated cells). Many of the chromosomal rear-
rangements induced by heavy ions are not transmitted to the progeny of 
surviving cells, albeit a higher fraction of complex rearrangements is still 
observed in the survivors. Part d is modified, with permission, from ReF. 42 
 radiation research society (2002).
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Future directions
Ground-based experimentation is the key to 
understanding the risks associated with space 
radiation exposure; flight experiments are 
difficult, expensive and poorly reproducible, 
the dose rate is too low to get useful data 
in reasonable time, and experiments in the 
past have yielded no major findings110–111. 
The NASA-funded Space Radiation Health 
Program112 is built upon the capabilities of 
the NASA Space Radiation Laboratory at the 
Brookhaven National Laboratory (upton, 
New York, uSA), and has produced experi-
mental data in the past few years of great 
relevance for reducing uncertainty on risk 
assessment. To foster European research in 
the field, the ESA has also recently initiated a 
ground-based radiobiology program113, which 
will be located at the high-energy synchrotron 
of the Gesellschaft für Schwerionenforschung 
in Darmstadt, Germany.
Research in this field is also essential for 
heavy-ion cancer therapy (hadrontherapy) 
on Earth, in which beams of high-energy 
carbon ions are used to sterilize solid 
cancers114–115. One major problem related 
to this treatment is the risk of secondary 
cancer, especially for paediatric patients116–117. 
Information on heavy-ion cancer risk sought 
by researchers in space radiation is also 
essential for estimating the incidence of sec-
ondary malignancies in these patients, and 
therefore the two research fields share many 
common issues and concerns118.
Although translation from basic research 
to cancer risk assessment is far from straight-
forward, for Moon base activities cancer risk 
does not appear to be a showstopper, but the 
uncertainty is still too high for a go or no-go 
decision on the mission to Mars. Cosmic 
radiation exposure certainly presents a major 
hurdle for extended space exploration, but it 
can be better understood and therefore miti-
gated. A fruitful NASA–ESA collaboration in 
accelerator-based research should be fostered 
in future years, in order to reach a consensus 
on radiation cancer risk for a Mars mission 
within the next 10 years or so. Intensified 
research on countermeasures will be needed 
in order for such a mission to become a reality.
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